Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication August 15, 2011
- Accepted for publication December 16, 2011
- Published online April 2, 2012.
Article Versions
- previous version (March 12, 2012 - 05:27).
- previous version (March 12, 2012 - 09:24).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2012 by the Society of Nuclear Medicine, Inc.
Author Information
- Gabriela Kramer-Marek*,1,
- Merel Gijsen*,2,
- Dale O. Kiesewetter3,
- Ruth Bennett2,
- Ioannis Roxanis4,
- Rafal Zielinski1,
- Anthony Kong2 and
- Jacek Capala1
- 1Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
- 2Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
- 3National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, Maryland; and
- 4Department of Cellular Pathology, Oxford University Hospitals and Oxford Biomedical Research Centre, Oxford, United Kingdom
- For correspondence or reprints contact either of the following: Jacek Capala, National Cancer Institute, NIH, 6130 Executive Blvd., Room 6010, Rockville, MD 20852-7440. E-mail: capalaj{at}mail.nih.gov
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine
- Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation In Vivo
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
- PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model
- Reply: PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model